MEDI0680

BIOLOGICAL2 trials

Sponsors

MedImmune LLC, MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC

Conditions

Clear Cell Renal Cell CarcinomaKidney CancerSelect Advanced Malignanciesclear-cell renal cell carcinoma (ccRCC) kidney cancer

Phase 1

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

CompletedNCT02118337

MedImmune LLCClear Cell Renal Cell Carcinoma, Kidney Cancer, Select Advanced Malignancies

Start: 2014-05-19End: 2020-03-17Updated: 2021-06-01

Phase 2

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies

Active, not recruitingNL-OMON47649

MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLCclear-cell renal cell carcinoma (ccRCC) kidney cancer

Start: 2018-03-06Target: 10Updated: 2024-02-28

Related Papers

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Journal for ImmunoTherapy of Cancer2019-08-2230 citations

Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations

Journal for ImmunoTherapy of Cancer2015-12-0134 citations

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

Journal of Clinical Oncology2015-05-207 citations